Abstract
BACKGROUND A key trial (NCT04308668) of post-exposure prophylaxis found hydroxychloroquine-associated (HCQ) reductions of Covid-19 by 17% overall and 31% to 49% in subgroups. To understand these trends, we re-analyzed the dataset.
METHODS Our protocol conformed to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT). We compared the incidence of Covid-19 after HCQ or placebo, stratifying by intervention lag, age, and gender.
RESULTS Newly requested data missing from the dataset revealed that 52% and 19% of subjects received medication 1-2 days after intended and assumed overnight delivery or four-day intervention lag respectively. After re-analysis, we found reduced HCQ-associated incidence of Covid-19 with Early (up to 3 days post-exposure) (RR 0.58, 95%CI 0.35 - 0.97; p=0.044; NNT 14.5) but not Late (RR 1.22, 95%CI 0.72 - 2.04) prophylaxis.
We found a significant HCQ-associated Covid-19 reduction in subjects 18 to 45 years old with Early (RR 0.54, 95%CI 0.29-0.97; p=0.0448, NNT 11.5) but not Late (RR 1.02, 95%CI 0.55-1.89) prophylaxis, attenuated in older subjects (RR 0.75, 95%CI 0-27-2.05) and by co-morbidities. Although, we did not detect effects of gender, folate, zinc, or ascorbate, confounding effects cannot be excluded.
CONCLUSIONS Using novel data and prospective re-analysis, hydroxychloroquine, in an age-dependent manner, was associated with reduced Covid-19 compatible illness when supplied for post-exposure prophylaxis between 1 and 3 days after high- or moderate-risk exposure, at higher loading and maintenance doses than in similar studies. The original study conclusions are controverted, and our finding warrants prospective confirmation.
Protocol registered at Open Science Framework: osf.io/fqtnw (last revised September 27, 2020,
Highlights
Missing data integrated with dataset re-analysis reversed findings of original study
Hydroxychloroquine associated reduction (42%) of Covid-19 compatible illness found
Effect in Post-exposure Prophylaxis when received 1-3 days after exposure
Risk Ratio 0.58 (95% CI 0.35-0.97, p=0.044, NNT14.5)
Findings controvert the conclusions of original study
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04308668
Clinical Protocols
https://www.medrxiv.org/content/10.1101/2020.08.19.20178376v2
Funding Statement
There is no external support for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval was required for this work. This is a re-analysis of a de-identified, publicly released dataset obtained from an IRB-supervised study. Additional requested data were de-identified data and provided after we had been advised that the Privacy Officer of the University of Minnesota would be consulted to ensure regulatory compliance.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding source: None
Versions 3.1-3.4: Revisions since version 2 of this manuscript was pre-printed December 12, 2020. i)Analysis confirming Watanabe, considering subjects becoming Covid-19 positive after the five-day treatment period (Table S 7). Comment added in discussion. ii)Abella, Bhattacharya. references and comments removed (to preserve wound count and reference limit) iii)Yang [37] reference inserted, noting their independent observation regarding the shipping time issue, recently brought to our attention. iv)Revised discussion of statistical limitations, Mudge et al., reference added. v)Plain language summary moved to Supplement vi)CDC reference [38] removed, duplicates information in WHO reference. [39] vii)Pharmacokinetic study by Boulware group referenced [40] and integrated into discussion of comparable studies. viii)Pragmatic trial reference replaced with better citation. ix)Table 5, weight added x)Typos and word economy, update references and format xi)Running and extended title xii)Clarifications and additional analyses to address comments made on medrxiv. These do not affect study results or interpretation. a.Clarification regarding <day on> vs. <days from> nomenclature added throughout. b.Clarification of variables used in different versions of the dataset (Supplement), including a newly circulating, but inaccurate revision (10/26). c.Sensitivity analysis using pooled placebo cohort to compare time-related effects. d.Sensitivity analysis based on Figure 1 of Nicol et al. [26] xiii)Title change to <novel, missing, data> xiv)Highlights added
Data Availability
Microsoft Excel files will be available on reasonable request up to one year after publication to qualified investigators subject to an agreed upon data sharing agreement. The source dataset is available from the original authors.
Abbreviations
- HCQ
- Hydroxychloroquine (and its salts)
- HCW
- Health Care Worker
- ITT
- Intent to Treat
- mITT
- Modified Intent to Treat
- NNT
- Number Needed to Treat
- PCR
- Polymerase Chain Reaction
- PEP
- Post-Exposure Prophylaxis
- PET
- Post Exposure Treatment
- PPE
- Personal Protective Equipment
- PrEP
- Pre-Exposure prophylaxis
- RCT
- Randomized Clinical Trial
